GlassScriptPhysician profile
Marcy D Markes
NPI 1962683995
$92,344.64
in general payments reported to CMS, 2019-2025
37 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19K · 2022: $16K · 2023: $24K · 2024: $19K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Food and Beverage: $12K · Travel and Lodging: $5,628 · Consulting Fee: $4,246 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,043.00 |
| Food and Beverage | $12,059.23 |
| Travel and Lodging | $5,628.00 |
| Consulting Fee | $4,246.00 |
| Education | $113.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $40,352.71 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Genzyme Corporation | $17,469.39 | 2021-2025 | |
| Grifols USA, LLC | $13,941.84 | 2021-2025 | Prolastin-C Liquid, Xembify |
| Regeneron Healthcare Solutions, INC. | $11,892.75 | 2021-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $2,229.28 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,687.12 | 2021 | |
| Glaxosmithkline, LLC. | $949.46 | 2021-2025 | Nucala |
| Genentech USA, INC. | $472.77 | 2021-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $417.47 | 2022-2025 | Cuvitru, Takhzyro, Hyqvia |
| Amgen INC. | $301.18 | 2021-2025 | Tezspire |
| Abbvie INC. | $242.76 | 2023-2024 | |
| Grifols Shared Services North America, INC. | $240.00 | 2023 | Prolastin-C Liquid |
| Neurocrine Biosciences, INC. | $237.47 | 2023 | Ongentys, Ingrezza |
| Optinose US, INC. | $212.36 | 2021-2025 | |
| Incyte Corporation | $159.31 | 2025 | Opzelura |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $129.33 | 2021-2023 | Auvi-Q |
| Actelion Pharmaceuticals US, INC. | $125.74 | 2024 | Uptravi, Opsumit |
| Kyowa Kirin, INC. | $124.81 | 2024 | Nourianz |
| Lilly USA, LLC | $112.71 | 2025 | Ebglyss |
| Ars Pharmaceuticals Operations, INC. | $111.80 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $109.24 | 2021-2025 | |
| Horizon Therapeutics Plc | $95.78 | 2021-2023 | Actimmune |
| Blueprint Medicines Corporation | $88.08 | 2023-2025 | Ayvakit |
| Greer Laboratories, INC. | $77.61 | 2023-2024 | Oralair, Palforzia |
| Viiv Healthcare Company | $74.33 | 2025 | Apretude |
| Lundbeck LLC | $64.79 | 2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.39 | 2021-2022 | |
| Pfizer INC. | $56.49 | 2021 | |
| Biocryst US Sales Co., LLC | $56.08 | 2021 | |
| Ionis Pharmaceuticals, INC. | $49.96 | 2025 | Dawnzera |
| Csl Behring | $41.60 | 2025 | Hizentra |
| Galderma Laboratories, L.P. | $33.02 | 2025 | Nemluvio |
| Verona Pharma, INC. | $32.29 | 2025 | Ohtuvayre |
| Pharming Healthcare, INC. | $31.27 | 2021-2023 | Ruconest |
| Inspire Medical Systems, INC. | $25.77 | 2023 | Inspire |
| Sanofi US Services INC. | $25.04 | 2025 | |
| Alk-Abello, INC | $15.64 | 2025 | Standardized Mite D. Farinae, Alternaria Tenuis, Timothy, Standardized |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcy Markes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.